Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study

• Published in: Psychiatry research Vol. 269; pp. 207 - 211
• Main Authors: Chen, Mu-Hong, Li, Cheng-Ta, Lin, Wei-Chen, Hong, Chen-Jee, Tu, Pei-Chi, Bai, Ya-Mei, Cheng, Chih-Ming, Su, Tung-Ping
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.11.2018
• Subjects: Adult; Antidepressive Agents - administration & dosage; CRP; Cytokines; Depressive Disorder, Treatment-Resistant - blood; Depressive Disorder, Treatment-Resistant - drug therapy; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; IL-6; Inflammation - blood; Inflammation - drug therapy; Inflammation Mediators - antagonists & inhibitors; Inflammation Mediators - blood; Infusions, Intravenous; Ketamine; Ketamine - administration & dosage; Male; Middle Aged; Time Factors; TNF-α; Treatment Outcome; Treatment-resistant depression; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Tumor Necrosis Factor-alpha - blood; CRP; Ketamine; Cytokines; TNF-α; IL-6; Treatment-resistant depression

•A single dose of ketamine infusion reduces TNF-α levels at 40 min and 240 min postinfusion.•There is a positive correlation between changes in cytokine levels after ketamine infusion and improvements in depressive symptoms.•The rapid suppression of proinflammatory cytokines may contribute to the ra...